APRIL 21, 2026 AT 02:31 PM

Regeneron (REGN) announces positive results from the Phase 3 NIMBLE trial evaluating investigational cemdisiran in adults with generalized myasthenia gravis

Importance

Level 1

#REGENERON PHARMACEUTICALS INC #REGN.US #EQUITIES #EU SESSION #US SESSION #BIOTECHNOLOGY #BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES #S&P 500 INDEX #NASDAQ 100 INDEX #REGN #US EQUITIES

© 2026 Newsquawk. All rights reserved.